Yonkenafil hydrochloride

Overview

Yonkenafil (Tunodafil) hydrochloride, a novel phosphodiesterase 5 ( PDE5 ) inhibitor, is effective in reducing cerebral infarction, neurological deficits, edema, and neuronal damage in the infarcted area. Yonkenafil (Tunodafil) hydrochloride may improve cognitive function by modulating neurogenesis and has a potential therapeutic effect on Alzheimer's disease.

Application

Products | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Colorectal Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Neurological Disease | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > Phosphodiesterase (PDE)

Product Information

• Catalog No.: HY-125095
• CAS No.: 804519-64-0
• Molecular Formula: C24H34ClN5O4S
• Molecular Weight: 524.08
• Purity: 99.43%
• Storage: 4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
• Solubility: ≥ 2.5 mg/mL (4.77 mM); Clear solution
• Availability: In-stock

Source

Original product source